Monoclonal antibodies: From structure to therapeutic application

Pharmaceutical Biotechnology: Fundamentals and Applications, Fourth Edition

Volumn , Issue , 2013, Pages 143-178

  Davis, John D ^a   Deng, Rong ^a   Andrew Boswell, C ^a   Zhang, Yi ^a   Li, Jing ^a   Fielder, Paul ^a   Joshi, Amita ^a   Kenkare Mitra, Saraswati ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; ONCOLOGY; PATIENT TREATMENT; SURFACE PLASMON RESONANCE;

CHEMOTHERAPEUTIC TREATMENTS; HYBRIDOMA TECHNOLOGY; INFLAMMATORY DISEASE; SCIENTIFIC BREAKTHROUGH; TECHNOLOGICAL EVOLUTION; THERAPEUTIC APPLICATION; THERAPEUTIC MODALITY; THERAPEUTIC MONOCLONAL ANTIBODIES;

DISEASES;

EID: 84897058336     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6486-0_7     Document Type: Chapter

References (177)

1. Aarons L, Karlsson MO et al (2001) Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci 13(2): 115-122
2. Actemra ® (Tocilizumab) (2010) Prescribing information. Genentech Inc., South San Francisco
3. Adcetris ® (Brentuximab vedotin) (2011) Prescribing information. Seattle Genetics Inc., Bothell
4. Agoram BM, Martin SW, van der Graaf PH (2007) The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today 12(23-24): 1018-1024
5. Albrecht H, DeNardo SJ (2006) Recombinant antibodies: from the laboratory to the clinic. Cancer Biother Radiopharm 21(4): 285-304
6. Amevive ® (Alefacept) (2003) Amevive prescribing information. Biogen Inc., Cambridge
7. Arzerra® (ofatumumab) (2009) Arzerra prescribing information. GlaxoSmithKline, Research Triangle Park
8. Avastin ® (2004) Avastin (Bevacizumab) prescribing information. Genentech Inc., South San Francisco
9. Baert F, Noman M et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7): 601-608
10. Bauer RJ, Dedrick RL et al (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27(4): 397-420
11. Baxter LT, Zhu H et al (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6): 1517-1528
12. Baxter LT, Zhu H et al (1995) Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55(20): 4611-4622
13. Bazin-Redureau MI, Renard CB et al (1997) Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49(3): 277-281
14. Benlysta ® (belimumab) (2011) Benlysta prescribing information. Human Genome Sciences Inc., Rockville
15. Berger MA, Masters GR et al (2005) Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776. 1 in a murine model of human ovarian cancer. Cancer Biother Radiopharm 20(6): 589-602
16. Bexxar (2003) Bexxar (Tositumomab) prescribing information. Corixa Corp/GlaxoSmithKline, Seattle/Philadelphia
17. Boswell CA, Brechbiel MW (2007) Development of radioimmunotherapeutic and diagnostic antibodies: an insideout view. Nucl Med Biol 34(7): 757-778
18. Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35(8): 763-766
19. Brambell F, Hemmings W et al (1964) A theoretical model of gamma-globulin catabolism. Nature 203: 1352-1355
20. Bugelski PJ, Herzyk DJ et al (2000) Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 19(4): 230-243
21. Bunescu A, Seideman P et al (2004) Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 31(12): 2347-2355
22. Campath ® (Alemtuzumab) (2009) Campath prescribing information. Genzyme Inc., Cambridge
23. Cartron G, Watier H et al (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9): 2635-2642
24. Chien, JY, Friedrich S et al (2005) Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 7(3): E544-559
25. Cimzia ® (2011) Cimzia (Certolizumab pegol) prescribing information. UCB Inc., Smyrna
26. Clarke J, Leach W et al (2004) Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 40(3): 219-226
27. Coffey GP, Fox JA et al (2005) Tissue distribution and receptormediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33(5): 623-629
28. Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18(1): 7-15
29. Cornillie F, Shealy D et al (2001) Infliximab induces potent antiinfl ammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15(4): 463-473
30. Dall'Ozzo S, Tartas S et al (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64(13): 4664-4669
31. Danilov SM, Gavrilyuk VD et al (2001) Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280(6): L1335-L1347
32. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1(5): 435-461
33. Dedrick RL, Walicke P et al (2002) Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 9(2-4): 181-186
34. den Broeder A, van de Putte L et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29(11): 2288-2298
35. Deng R, Iyer S, Theil FP et al (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. What have we learned? MAbs 3(1): 61-66
36. Dong JQ, Salinger DH, Endres CJ et al (2011) Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50: 131-142
37. Dickinson BL, Badizadegan K et al (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104(7): 903-911
38. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10): 633-659
39. Dowell JA, Korth-Bradley J et al (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41(11): 1206-1214
40. Druet P, Bariety J et al (1978) Distribution of heterologous antiperoxidase antibodies and their fragments in the superficial renal cortex of normal Wistar-Munich rat: an ultrastructural study. Lab Invest 39(6): 623-631
41. Duconge J, Castillo R et al (2004) Integrated pharmacokineticpharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci 21(2-3): 261-270
42. Erbitux ® (2004) Erbitux (Cetuximab) prescribing information. Imclone Systems Inc., Bristol-Myers Squibb Company, Branchburg/Princeton
43. Ferl GZ, Wu AM et al (2005) A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33(11): 1640-1652
44. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50(5): 1412-1419
45. Ghetie V, Hubbard JG et al (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26(3): 690-696
46. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 36(4): 341-351
47. Gibiansky L, Frey N (2012) Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn 39(1): 5-16
48. Gillies SD, Lo KM et al (2002) Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 8(1): 210-216
49. Gillies SD, Lan Y et al (1999) Improving the efficacy of antibodyinterleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res 59(9): 2159-2166
50. Girish S, Martin SW, Peterson MC et al (2011) AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J 13(3): 405-416
51. Goldsby RA, Kindt TJ et al (1999) Immunoglobulins: structure and function. In: Kuby immunology, 4th edn. W. H. Freeman and Company, New York
52. Gottlieb AB, Miller B et al (2003) Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 7(3): 198-207
53. Hayashi N, Tsukamoto Y et al (2007) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63(5): 548-561
54. Herceptin ® (2006) Herceptin (Trastuzumab) prescribing information. Genentech Inc., South San Francisco
55. Hervey PS, Keam SJ (2006) Abatacept. BioDrugs 20(1): 53-61, discussion 62
56. Hinton PR, Xiong JM et al (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176(1): 346-356
57. Holmes D (2011) Buy buy bispecific antibodies. Nat Rev Drug Discov 10: 798-800
58. Hooks MA, Wade CS et al (1991) Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11(1): 26-37
59. Huang L, Biolsi S et al (2006) Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem 349(2): 197-207
60. Huang S-M, Zhao H, Lee J-I et al (2010) Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 87(4): 497-503
61. Humira ® (2007) Humira (Adalimumab) prescribing information. Abbott Laboratories, Chicago
62. ICH (1997a) ICH harmonized tripartite guideline M3: nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals
63. ICH (1997b) ICH harmonized tripartite guideline S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals
64. Ilaris ® (canakimumab) (2011) Ilaris prescribing information. Novartis Corp, East Hanover
65. Jolling K, Perez Ruixo JJ et al (2005) Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 24(5): 465-475
66. Joshi A, Bauer R et al (2006) An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 46(1): 10-20
67. Junghans RP (1997) Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16(1): 29-57
68. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 93(11): 5512-5516
69. Kadcyla® (ado-trastuzumab emtansine) (2013) Kadcyla prescribing information. Genentech Inc., South San Francisco
70. Kagan L, Abraham AK, Harrold JM et al (2010) Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27: 920-932
71. Kairemo KJ, Lappalainen AK et al (2001) In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate. J Nucl Med 42(3): 476-482
72. Kelley SK, Gelzleichter T et al (2006) Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148(8): 1116-1123
73. Kleiman NS, Raizner AE et al (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26(7): 1665-1671
74. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517): 495-497
75. Kolar GR, Capra JD (2003) Immunoglobulins: structure and function. In: Paul WE (ed) Fundamental immunology, 5th edn. Lippincott Williams & Wilkins, Philadelphia
76. Koon HB, Severy P et al (2006) Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res 30(2): 190-203
77. Kovarik JM, Nashan B et al (2001) A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69(4): 201-209
78. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46(1): 1-23, quiz 23-6
79. Kuus-Reichel K, Grauer LS et al (1994) Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1(4): 365-372
80. Lee H, Kimko HC et al (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73(4): 348-365
81. Lee JI, Zhang L, Men A et al (2010) CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 49(5): 295-310
82. Lin YS, Nguyen C et al (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288(1): 371-378
83. Ling J, Zhou H, Jiao Q et al (2009) Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49(12): 1382-1402
84. Lobo ED, Hansen RJ et al (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11): 2645-2668
85. Looney RJ, Anolik JH et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8): 2580-2589
86. LoRusso PM, Weiss D, Guardino E et al (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17(20): 6437-6447
87. Lu D, Modi S, Elias A et al (2011) Pharmacokinetics (PK) of Trastuzumab emtansine and paclitaxel or docetaxel in patients with HER2-positive MBS previously treated with trastuzumab-containing regimen. In: 34th annual San Antonio breast cancer symposium. San Antonio
88. Lu D, Burris H, Wang B et al (2012) Drug interaction potential of trastuzumab emtansine in combination with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab 13: 911-922
89. Lucentis ® (2006) Lucentis (Ranibizumab) prescribing information. Genentech Inc., South San Francisco
90. Ma P, Yang BB, Wang YM et al (2009) Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 49(10): 1142-1156
91. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR (2003) Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307(3): 969-976
92. Mager DE, Woo S, Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24: 16-24
93. Mahmood I (2005) Prediction of concentration-time profiles in humans. In: Interspecies pharmacokinetics scaling. Pine House Publishers, Rockville, pp 219-241
94. Mahmood I, Green MD (2005) Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44(4): 331-347
95. Mahmood I (2009) Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98: 3850-3861
96. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macrarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9): 1552-1563
97. Martin-Jimenez T, Riviere JE (2002) Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. J Pharm Sci 91(2): 331-341
98. McClurkan MB, Valentine JL et al (1993) Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther 266(3): 1439-1445
99. McLaughlin P, Grillo-Lopez AJ et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8): 2825-2833
100. Medesan C, Matesoi D et al (1997) Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 158(5): 2211-2217
101. Meibohm B, Derendorf H (2002) Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 91(1): 18-31
102. Meijer RT, Koopmans RP et al (2002) Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 300(1): 346-353
103. Meredith PA, Elliott HL et al (1991) Dose-response clarification in early drug development. J Hypertens Suppl 9(6): S356-S357
104. Morris EC, Rebello P et al (2003) Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102(1): 404-406
105. Mortensen DL, Walicke PA et al (2005) Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 45(3): 286-298
106. Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10(1): 84-96
107. Mould DR, Davis CB et al (1999) A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 66(3): 246-257
108. Nakakura EK, McCabe SM et al (1993) Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. Transplantation 55(2): 412-417
109. Nestorov I, Zitnik R et al (2004) Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 31(6): 463-490
110. Newkirk MM, Novick J et al (1996) Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 106(2): 259-264
111. Ng CM, Joshi A et al (2005) Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22(7): 1088-1100
112. Ng CM, Stefanich E et al (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23(1): 95-103
113. Norman DJ, Chatenoud L et al (1993) Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 25 (2 Suppl 1): 89-92
114. Nulojix® (belatacept) (2011) Nulojix prescribing information. Bristol Myers Squibb Inc, Princeton
115. Ober RJ, Radu CG et al (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13(12): 1551-1559
116. Oitate M, Masubuchi N, Ito T et al (2011) Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 26: 423-430
117. Oitate M, Nakayama S, Ito T et al (2012) Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by speciesinvariant time method. Drug Metab Pharmacokinet 27: 354-359. Online advance publication at http: //www.jstage. jst. go. jp/article/dmpk/advpub/0/advpub_1111290286/_article
118. Papp K, Bissonnette R et al (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45(5): 665-674
119. Petkova SB, Akilesh S et al (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18(12): 1759-1769
120. Prabhu S, Boswell SC, Leipold D et al (2011) Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv 2(6): 769-791
121. Presta LG (2002) Engineering antibodies for therapy. Curr Pharm Biotechnol 3(3): 237-256
122. Presta LG, Shields RL et al (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30(4): 487-490
123. Prolia® (denosumab) (2010) Prolia prescribing information. Amgen Inc., Thousand Oaks
124. Radin A, Marbury T, Osgood G, Belomestnov P (2010) Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease. J Clin Pharmacol 50: 835-841
125. Raptiva ® (2004) Raptiva (Efalizumab) prescribing information. Genentech Inc., South San Francisco
126. Remicade ® (2006) Remicade (Infliximab) prescribing information. Centocor Inc., Malvern
127. Rituxan ® (2006) Rituxan (Rituximab) prescribing information. Genentech Inc. /Biogen Inc., South San Francisco/Cambridge
128. Roopenian DC, Christianson GJ et al (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170(7): 3528-3533
129. Roskos LK, Davis CG et al (2004) The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 61(3): 108-120
130. Schror K, Weber AA (2003) Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 15(2): 71-80
131. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39: 67-86
132. Sheiner L, Wakefield J (1999) Population modelling in drug development. Stat Methods Med Res 8(3): 183-193
133. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3): 275-291
134. Shields RL, Namenuk AK et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9): 6591-6604
135. Sifontis NM, Benedetti E, Vasquez EM (2002) Clinically signifi cant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 34: 1730-1732
136. Simister NE, Mostov KE (1989a) An Fc receptor structurally related to MHC class I antigens. Nature 337(6203): 184-187
137. Simister NE, Mostov KE (1989b) Cloning and expression of the neonatal rat intestinal Fc receptor, a major histo-compatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 54(Pt 1): 571-580
138. Simulect ® (2005) Simulect (Basiliximab) prescribing information. Novartis Pharmaceuticals, East Hanover
139. Simponi ® (2009) Simponi (golimumab) prescribing information. Janssen Biotech Inc., Horsham
140. Soliris ® (eculizumab) (2007) Soliris prescribing Information. Alexion Pharmaceuticals Inc, Cheshire
141. Spiekermann GM, Finn PW et al (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 196(3): 303-310
142. Straughn AB (2006) Limitations of noncompartmental pharmacokinetic analysis of biotech drugs. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs. Weinheim, Wiley, pp 181-188
143. Subramanian GM, Cronin PW et al (2005) A phase 1 study of PAmab, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 41(1): 12-20
144. Sun YN, Lu JF et al (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45(4): 468-476
145. Synagis (2004) Synagis (Palivizumab) prescribing information. MedImmune Inc. /Abbott Laboratories Inc., Gaithersburg/Columbus
146. Tabrizi MA, Tseng CM et al (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11(1-2): 81-88
147. Tang H, Mayersohn M (2005) Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 33(9): 1288-1293
148. Tang L, Persky AM, Hochhaus G, Meibohm B (2004) Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93(9): 2184-2204
149. Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1): S37-S47
150. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12): 1421-1434
151. Tokuda Y, Watanabe T et al (1999) Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. Br J Cancer 81(8): 1419-1425
152. Tysabri ® (2006) Tysabri (Natalizumab) prescribing information. Elan Pharmaceuticals Inc. /Biogen Idec Inc., San Diego/Cambridge
153. Umana P, Jean-Mairet J et al (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity. Nat Biotechnol 17(2): 176-180
154. Vaccaro C, Bawdon R et al (2006) Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 103(49): 18709-18714
155. Vaishnaw AK, TenHoor CN (2002) Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 29(5-6): 415-426
156. Vasquez EM, Pollak R (1997) OKT3 therapy increases cyclosporine blood levels. Clin Transplant 11(1): 38-41
157. Vectibix ® (2006) Vectibix (Panitumumab) prescribing information. Amgen Inc, Thousand Oaks
158. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K et al (2007) A phase I/II randomized open-label multi-center trial of efalizumab, a humanized ani-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 7: 1770-1777
159. Wang W, Prueksaritanont T (2010) Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 31: 253-263
160. Wang W, Singh S et al (2007) Antibody structure, instability, and formulation. J Pharm Sci 96(1): 1-26
161. Watanabe N, Kuriyama H et al (1988) Continuous internalization of tumor necrosis factor receptors in a human myosarcoma cell line. J Biol Chem 263(21): 10262-10266
162. Weiner LM (2006) Fully human therapeutic monoclonal antibodies. J Immunother 29(1): 1-9
163. Weisman MH, Moreland LW et al (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25(6): 1700-1721
164. Werther WA, Gonzalez TN et al (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157(11): 4986-4995
165. Wiseman GA, White CA, Sparks RB et al (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39(1-2): 181-194
166. Wurster U, Haas J (1994) Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 57(Suppl): 21-25
167. Xolair ® (2003) Xolair (Omalizumab) [prescribing information]. Genentech Inc/Novartis Pharmaceuticals Corp., South San Francisco/East Hanover
168. Yervoy ® (2011) Yervoy (ipilimumab) prescribing information. Bristol Myers Squibb Inc, Princeton
169. Yim DS, Zhou H et al (2005) Population pharmacokinetic analysis and simulation of the time-concentration profi le of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 45(3): 246-256
170. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363: 1812-1821
171. Zenapax ® (2005) Zenapax (Daclizumab) prescribing information. Hoffman-La Roche Inc, Nutley
172. Zevalin ® (2002) Zevalin (ibritumomab tiuxetan) prescribing information. Spectrum Pharmaceuticals, Irvine
173. Zheng Y, Scheerens H, Davis JC et al (2011) Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 89(2): 283-290
174. Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45(5): 490-497
175. Zhou H, Mayer PR et al (2004) Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 44(11): 1235-1243
176. Zhu Y, Hu C, Lu M et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2): 162-175
177. Zia-Amirhosseini P, Minthorn E et al (1999) Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291(3): 1060-1067